The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Researchers have found in a new study that in a real-world Japanese cohort, deucravacitinib 6 mg provided sustained disease ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...